Published: 21 January 2020
Authors: Varun Shah, MD Bryan Husta, MD, FCCP Atul Mehta, MD, FCCP Byron Patton, MD Viera Lakticova, MD Suhail Raoof, MD, Master FCCP et al
Source: This abstract has been sourced from NZ Respiratory Research Review Issue 180
The aim of this study was to assess any association between use of inhaled corticosteroids (ICS) and tracheobronchomalacia (TBM).
This study was a retrospective analysis of patients with asthma and COPD, with and without TBM. Patients were diagnosed with TBM on the basis of CT imaging, flexible bronchoscopy, or both. Patients were deemed to be on ICS if they had been receiving treatment for at least 3 months. Simple logistic regression models were used to assess the association between TBM status and each proposed factor. A multivariable logistic regression model was used to assess the association between TBM and steroid dose.
A total of 463 patients with COPD (n = 153) and asthma (n = 310) were studied. In multivariate analysis, the odds of TBM were 3.5 times higher in patients on high-dose steroids compared with patients not on steroids (OR, 3.5; 95% CI, 1.4-8.5; P = .007). Age ( P < .0001), presence of gastroesophageal reflux disease ( P < .0001), use of long-acting muscarinic antagonists ( P < .0001), and type of pulmonary disease ( P = .002) were also associated with TBM. In patients using ICS, the odds of having TBM were 2.9 times greater in patients on high-dose inhaled steroids compared with those on low-dose inhaled steroids (OR, 2.9; 95% CI, 1.2-7.1; P = .02). Age ( P = .003), presence of gastroesophageal reflux disease ( P = .002), use of long-acting muscarinic antagonists ( P = .004), type of ICS ( P = .04), and number of months on ICS ( P < .0001) were all associated with TBM.
There was a significant association between ICS use in higher doses for a longer duration of time with TBM. Prospective randomized controlled trials are needed to show causality of this observed association.
